Trial Profile
An Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) Monotherapy in Subjects with Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms Checkmate 171
- Sponsors Bristol-Myers Squibb
- 17 Sep 2021 Status changed from active, no longer recruiting to completed.
- 09 Jul 2021 Planned End Date changed from 31 May 2021 to 8 Oct 2021.
- 06 Jun 2021 This trial has been completed in Hungary according to European Clinical Trials Database record.